AU2021383424A1 - Administration of sting agonist, checkpoint inhibitors, and radiation - Google Patents

Administration of sting agonist, checkpoint inhibitors, and radiation Download PDF

Info

Publication number
AU2021383424A1
AU2021383424A1 AU2021383424A AU2021383424A AU2021383424A1 AU 2021383424 A1 AU2021383424 A1 AU 2021383424A1 AU 2021383424 A AU2021383424 A AU 2021383424A AU 2021383424 A AU2021383424 A AU 2021383424A AU 2021383424 A1 AU2021383424 A1 AU 2021383424A1
Authority
AU
Australia
Prior art keywords
administered
day
compound
radiation
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021383424A
Other languages
English (en)
Other versions
AU2021383424A9 (en
Inventor
Yosuke Sato
Michael H. Shaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2021383424A1 publication Critical patent/AU2021383424A1/en
Publication of AU2021383424A9 publication Critical patent/AU2021383424A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Radiation-Therapy Devices (AREA)
AU2021383424A 2020-11-18 2021-11-18 Administration of sting agonist, checkpoint inhibitors, and radiation Pending AU2021383424A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063115398P 2020-11-18 2020-11-18
US63/115,398 2020-11-18
US202163140125P 2021-01-21 2021-01-21
US63/140,125 2021-01-21
US202163184295P 2021-05-05 2021-05-05
US63/184,295 2021-05-05
US202163275480P 2021-11-04 2021-11-04
US63/275,480 2021-11-04
PCT/IB2021/060679 WO2022107027A1 (en) 2020-11-18 2021-11-18 Administration of sting agonist, checkpoint inhibitors, and radiation

Publications (2)

Publication Number Publication Date
AU2021383424A1 true AU2021383424A1 (en) 2023-06-08
AU2021383424A9 AU2021383424A9 (en) 2024-02-08

Family

ID=79287967

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021383424A Pending AU2021383424A1 (en) 2020-11-18 2021-11-18 Administration of sting agonist, checkpoint inhibitors, and radiation

Country Status (9)

Country Link
US (1) US20240335464A1 (https=)
EP (1) EP4247385A1 (https=)
JP (1) JP2023550740A (https=)
KR (1) KR20230110254A (https=)
AU (1) AU2021383424A1 (https=)
CA (1) CA3196529A1 (https=)
MX (1) MX2023005695A (https=)
TW (1) TW202233206A (https=)
WO (1) WO2022107027A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026053158A1 (en) * 2024-09-06 2026-03-12 Takeda Pharmaceutical Company Limited Dazostinag or conjugates thereof for treatment of neuroendocrine neoplasms
WO2026053159A1 (en) * 2024-09-06 2026-03-12 Takeda Pharmaceutical Company Limited Dazostinag or conjugates thereof for treatment of adenoid cystic carcinomas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP2018090562A (ja) * 2016-12-01 2018-06-14 武田薬品工業株式会社 環状ジヌクレオチド
PE20210255A1 (es) * 2016-12-01 2021-02-10 Takeda Pharmaceuticals Co Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon)
AU2017378782A1 (en) * 2016-12-20 2019-07-04 Merck Sharp & Dohme Corp. Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
RU2020109328A (ru) * 2017-08-04 2021-09-06 Мерк Шарп И Доум Корп. Комбинации антагонистов pd-1 и бензо[b]тиофеновых агонистов sting для лечения рака
WO2020049534A1 (en) * 2018-09-07 2020-03-12 Novartis Ag Sting agonist and combination therapy thereof for the treatment of cancer
IL287938B2 (en) * 2019-05-10 2025-07-01 Takeda Pharmaceuticals Co Antibody-drug conjugates
TW202116330A (zh) * 2019-07-09 2021-05-01 日商武田藥品工業股份有限公司 Sting 促效劑及檢查點抑制劑之投與

Also Published As

Publication number Publication date
KR20230110254A (ko) 2023-07-21
CA3196529A1 (en) 2022-05-27
MX2023005695A (es) 2023-05-29
TW202233206A (zh) 2022-09-01
WO2022107027A1 (en) 2022-05-27
EP4247385A1 (en) 2023-09-27
US20240335464A1 (en) 2024-10-10
JP2023550740A (ja) 2023-12-05
AU2021383424A9 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
US20210069326A1 (en) Pd-l1 antagonist combination treatments
US12403154B2 (en) Administration of sting agonist and checkpoint inhibitors
US12097199B2 (en) Administration of SUMO-activating enzyme inhibitor and anti-CD20 antibodies
US20240335464A1 (en) Administration of sting agonist, checkpoint inhibitors, and radiation
US12419890B2 (en) Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
US20230218618A1 (en) Administration of sumo-activating enzyme inhibitor and anti-cd38 antibodies
CN116490244A (zh) Sting激动剂、检查点抑制剂和辐射的施用
NZ737018B2 (en) Pd-l1 antagonist combination treatments

Legal Events

Date Code Title Description
SREP Specification republished